Powder: -20°C for 3 years | In solvent: -80°C for 1 year
YXG-158 (Compound 23-h), an orally active androgen receptor (AR) degrader and cytochrome P450 17A1 (CYP17A1) inhibitor, exhibits AR degradation with a DC50 of 1.28 μM and CYP17A1 inhibition with an IC50 of 100 nM. It is under investigation for potential use in research on enzalutamide-resistant prostate cancer [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | YXG-158 (Compound 23-h), an orally active androgen receptor (AR) degrader and cytochrome P450 17A1 (CYP17A1) inhibitor, exhibits AR degradation with a DC50 of 1.28 μM and CYP17A1 inhibition with an IC50 of 100 nM. It is under investigation for potential use in research on enzalutamide-resistant prostate cancer [1]. |
Molecular Weight | 473.62 |
Formula | C30H36FN3O |
CAS No. | 2952994-34-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
YXG-158 2952994-34-0 Endocrinology/Hormones Androgen Receptor inhibitor inhibit